Tsuzurahara S, Sata M, Iwamoto O, Shichijo S, Kojiro M, Tanikawa K, Itoh K
Second Department of Medicine, Kurume University School of Medicine.
Jpn J Cancer Res. 1997 Sep;88(9):915-8. doi: 10.1111/j.1349-7006.1997.tb00469.x.
The aim of this study was to determine whether MAGE-4 protein is detectable in sera of patients with hepatocellular carcinoma and other liver diseases. An enzyme-linked immunosorbent assay was employed for detection of MAGE-4 protein in sera of liver disease patients, healthy men and women (control I) and those undergoing prostatic cancer screening (control II). MAGE-4 protein levels in sera of patients with hepatitis C virus-associated HCC (HCC-C) (n = 45, mean = 2.160 ng/ml) and HCV-associated cirrhosis (LC-C) (n = 55, 1.072 ng/ml) were significantly higher (P < 0.0001) than those of control I (0.327 ng/ml) or control II (0.394 ng/ml). MAGE-4 protein was positive in 21/45 (46.7%) HCC-C patients and 18/55 (32.7%) LC-C patients (cut-off, mean plus 2 SD in healthy controls) but in 0/12 (0%) hepatitis B virus-associated HCC (HCC-B) patients, 3/49 (6.1%) hepatitis B virus-associated LC (LC-B) patients, 4/47 (8.5%) alcoholic liver disease patients, and 1/49 (2.0%) controls. Serum MAGE-4 protein level may be useful as a marker for identification of LC-C patients suffering from HCC that is undetectable by presently available methods.
本研究的目的是确定在肝细胞癌患者和其他肝病患者的血清中是否可检测到MAGE-4蛋白。采用酶联免疫吸附测定法检测肝病患者、健康男性和女性（对照I）以及接受前列腺癌筛查者（对照II）血清中的MAGE-4蛋白。丙型肝炎病毒相关肝细胞癌（HCC-C）患者（n = 45，均值 = 2.160 ng/ml）和丙型肝炎病毒相关肝硬化（LC-C）患者（n = 55，1.072 ng/ml）血清中的MAGE-4蛋白水平显著高于对照I（0.327 ng/ml）或对照II（0.394 ng/ml）（P < 0.0001）。MAGE-4蛋白在21/45（46.7%）的HCC-C患者和18/55（32.7%）的LC-C患者中呈阳性（临界值为健康对照者均值加2个标准差），但在0/12（0%）的乙型肝炎病毒相关肝细胞癌（HCC-B）患者、3/49（6.1%）的乙型肝炎病毒相关肝硬化（LC-B）患者、4/47（8.5%）的酒精性肝病患者和1/49（2.0%）的对照者中呈阳性。血清MAGE-4蛋白水平可能作为一种标志物，用于识别目前现有方法无法检测到的患有肝细胞癌的LC-C患者。
